bioRxivBiophysics
Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition
Abstract
AbstractHypertrophic cardiomyopathies (HCM) result from distinct single-point mutations in sarcomeric proteins that lead to muscle hypercontractility. While different models account for a pathological increase in the power output, clear understanding of the molecular basis of dysfunction in HCM is the mandatory next step to improve current treatments. An optimized quasi-atomic model of the sequestered state of cardiac myosin coupled to X-ray crystallography and in silico analysis of the mechanical compliance of the lever arm allowed us to perform a systematic study for a large set of HCM mutations. We define different classes of mutations depending on their effects on lever arm compliance, sequestered state stability and motor functions. This work reconciles previous models and explains how distinct HCM mutations can have disparate effects on the motor mechano-chemical parameters and yet lead to the same disease. The framework presented here can guide future investigations aiming at finding HCM treatments.
- organism: human
- assay: structural biology
- research focus: chromatin & epigenetic regulation
- approach: biophysical modeling
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hypertrophic cardiomyopathy mutations at the folded-back sequestered β-cardiac myosin S1-S2 and S1-S1 interfaces release sequestered heads and increase myosin enzymatic activity
A. S. Adhikari, D. V. Trivedi, … K. M. Ruppel·bioRxiv·Jan 31, 2019
- Myosin motor domains carrying mutations implicated in early or late onset Hypertrophic Cardiomyopathy have similar properties
C. D. Vera, C. A. Johnson, … L. A. LEINWAND·bioRxiv·Aug 10, 2019
- Beyond the myosin mesa: a potential unifying hypothesis on the underlying molecular basis of hyper-contractility caused by a majority of hypertrophic cardiomyopathy mutations
Suman Nag, Darshan V Trivedi, … James A Spudich·bioRxiv·Jul 24, 2016
- Mutations in the catalytic domain of human β-cardiac myosin that cause early onset hypertrophic cardiomyopathy significantly increase the fundamental parameters that determine ensemble force and velocity
Arjun S Adhikari, Kristina B Kooiker, … Kathleen M Ruppel·bioRxiv·Aug 9, 2016
- Hypertrophic cardiomyopathy mutations in the pliant and light chain-binding regions of the lever arm of human β-cardiac myosin have divergent effects on myosin function
M. Morck, D. Bhowmik, … K. M. Ruppel·bioRxiv·Oct 11, 2021
- Hypertrophic cardiomyopathy mutations Y115H and E497D disrupt the folded-back state of human beta-cardiac myosin allosterically
N. Nandwani, D. Bhowmik, … K. M. Ruppel·bioRxiv·Feb 29, 2024